Free Trial

AEON Biopharma (AEON) 10K Form and Latest SEC Filings 2026

AEON Biopharma logo
$0.94 -0.01 (-1.05%)
Closing price 03:57 PM Eastern
Extended Trading
$0.94 +0.01 (+0.53%)
As of 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest AEON Biopharma SEC Filings & Recent Activity

AEON Biopharma (NASDAQ:AEON) has submitted 207+ documents to the U.S. Securities and Exchange Commission (SEC) since 2021. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form ARS submitted on April 29, 2026.

Form 4
AEON Biopharma, Inc. Reports Ownership Change on Apr. 3, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
AEON Biopharma Files Current Report on Apr. 3, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
AEON Biopharma Files Quarterly Report on Nov. 14, 2025

The 10-Q contains AEON Biopharma's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

AEON Biopharma SEC Filing History

Browse AEON Biopharma's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/29/2026 4:18 PM
AEON Biopharma (1837607) Filer
Form DEF 14A
04/29/2026 4:19 PM
AEON Biopharma (1837607) Filer
Form DEFA14A
04/29/2026 4:20 PM
AEON Biopharma (1837607) Filer
Form ARS
04/03/2026 5:22 PM
AEON Biopharma (1837607) Issuer
Bencich John (1477056) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/03/2026 5:22 PM
AEON Biopharma (1837607) Issuer
Bencich John (1477056) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/03/2026 3:05 PM
AEON Biopharma (1837607) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/11/2026 7:13 PM
AEON Biopharma (1837607) Issuer
Oh Chad (1882166) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:06 PM
AEON Biopharma (1837607) Issuer
Sy Jennifer (2023998) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:07 PM
AEON Biopharma (1837607) Issuer
Wilson Alexander Blair (1979602) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 7:40 PM
AEON Biopharma (1837607) Issuer
Bancroft Robert E. (2066370) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 3:05 PM
AEON Biopharma (1837607) Filer
Form 424B3
02/17/2026 11:15 PM
AEON Biopharma (1837607) Filer
Form EFFECT
02/09/2026 3:38 PM
AEON Biopharma (1837607) Filer
Form S-3
Registration statement under Securities Act of 1933  
01/29/2026 8:24 PM
AEON Biopharma (1837607) Subject
Daewoong Co., Ltd (1985493) Filed by
Form SCHEDULE 13D
01/29/2026 8:25 PM
AEON Biopharma (1837607) Issuer
Daewoong Co., Ltd (1985493) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/29/2026 8:03 PM
AEON Biopharma (1837607) Subject
Daewoong Co., Ltd (1985493) Filed by
Form SCHEDULE 13D/A
01/21/2026 3:06 PM
AEON Biopharma (1837607) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/12/2026 8:17 AM
AEON Biopharma (1837607) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/19/2025 3:01 PM
AEON Biopharma (1837607) Filer
Form PRE 14A
12/15/2025 3:11 PM
AEON Biopharma (1837607) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/04/2025 8:02 AM
AEON Biopharma (1837607) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2025 7:35 AM
AEON Biopharma (1837607) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/14/2025 7:40 AM
AEON Biopharma (1837607) Filer
Form DEFA14A
11/14/2025 7:31 AM
AEON Biopharma (1837607) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2025 7:30 AM
AEON Biopharma (1837607) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/14/2025 3:17 PM
AEON Biopharma (1837607) Subject
Alta Partners LLC (1896206) Filed by
Form SCHEDULE 13G/A
07/09/2025 11:33 AM
AEON Biopharma (1837607) Subject
Alta Partners LLC (1896206) Filed by
Form SCHEDULE 13G/A
06/11/2025 5:04 AM
AEON Biopharma (1837607) Filer
Form DEFR14A
05/30/2025 11:10 AM
AEON Biopharma (1837607) Subject
Chernett Jorey (2042077) Filed by
Form SCHEDULE 13G
05/23/2025 3:55 PM
AEON Biopharma (1837607) Issuer
Sy Jennifer (2023998) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:56 PM
AEON Biopharma (1837607) Issuer
Oh Chad (1882166) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:57 PM
AEON Biopharma (1837607) Issuer
Wilson Alexander Blair (1979602) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 4:04 PM
AEON Biopharma (1837607) Issuer
Thunen Shelley B (1297491) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:46 PM
AEON Biopharma (1837607) Issuer
FISCHER JOST (1366841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:50 PM
AEON Biopharma (1837607) Issuer
FISCHER JOST (1366841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:50 PM
AEON Biopharma (1837607) Issuer
Carter Eric G (1387660) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:51 PM
AEON Biopharma (1837607) Issuer
PALMISANO ROBERT J (1138646) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 3:50 PM
AEON Biopharma (1837607) Issuer
FISCHER JOST (1366841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/15/2025 6:21 PM
AEON Biopharma (1837607) Subject
L1 Capital Global Opportunities Master Fund, Ltd. (1702202) Filed by
Form SCHEDULE 13G/A
05/15/2025 5:35 PM
AEON Biopharma (1837607) Subject
S.H.N. Financial Investments Ltd. (1890802) Filed by
Form SCHEDULE 13G/A
05/15/2025 6:07 AM
AEON Biopharma (1837607) Subject
Polar Asset Management Partners Inc. (1326389) Filed by
Form SCHEDULE 13G/A
(Data available from 1/1/2016 forward)

AEON Biopharma SEC Filings - Frequently Asked Questions

AEON Biopharma (AEON) has submitted 207+ filings to the SEC since 2021. You can browse the complete history or filter by form type using the tools above.

AEON Biopharma's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form ARS submitted on April 29, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:AEON) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners